The MuLeVaClin consortium has been constructed around an integrated assembly of eminent scientific groups with acknowledged complimentary expertise in the fields of molecular biology, immunology, vaccinology, and clinical evaluation. The consortium includes eight partners, located in Spain, Portugal, Italy, Switzerland and the Czech Republic. The partners have been selected for their capability to cover all the aspects for this specific vaccine development. The consortium includes most renowned experts in the field of Leishmaniasis, with two National Health Centers for the surveillance of the disease: ISTITUTO SUPERIORE DI SANITA‘ (Italy) and the INSTITUTE OF HEALTH CARLOS III (Spain); two prestigious research centers such as: the CENTRO DE BIOLOGIA MOLECULAR “SEVERO OCHOA” of the UNIVERSITY AUTONOMA DE MADRID (Spain) and the INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR of UNIVERSITY of PORTO (Portugal); a renowned center with an extensive experience in clinical trials for tropical disease: the SWISS TROPICAL AND PUBLIC HEATH INSTITUTE (Switzerland), and three industrial partners: ETNA BIOTECH (Italy) a fully private research company owned by Indian Zydus Cadila Healthcare and part of Zydus' Vaccine Technology Center, with a strong expertise in R&D in vaccinology, from bench to the market; AMVAC AG (Switzerland) an ambitious SME focusing on the development of highly innovative vaccines for therapeutic and prophylactic purposes with GMP-grade vaccine manufacturing expertise; and the SME BIOTEST S.R.O. a well-known preclinical organisation specialised in toxicology. To enhance the likelihood of success the network includes collaborations with two leading organisations in the US: the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, the U.S.’s medical research agency, and the Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research and product development organization focused on infectious diseases of global importance.